Search clinical trials for: Preladenant

Total 13 results

Merck Sharp & Dohme LLC

Completed

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Parkinson's Disease
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

Parkinson Disease
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
Merck Sharp & Dohme LLC

Completed

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)

Parkinson Disease
Merck Sharp & Dohme LLC

Completed

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

Brain Diseases | Central Nervous System Diseases | Parkinson Disease | Movement Disorders | Neurodegenerative Diseases
Merck Sharp & Dohme LLC

Terminated

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664) (PARADYSE)

Parkinson Disease
Merck Sharp & Dohme LLC

Terminated

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

Parkinson Disease | Idiopathic Parkinson Disease
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

Parkinsonian Disorders | Dyskinesia, Drug-Induced | Akathisia, Drug-Induced
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Neoplasm

United States, Canada, Israel
Norwegian University of Science and Technology
AstraZeneca

Completed

Prophylactic Treatment of Episodic Cluster Headache

Cluster Headache

Norway
Merck Sharp & Dohme LLC

Completed

Dyskinesia in Parkinson's Disease (Study P04501)

Brain Diseases | Central Nervous System Diseases | Parkinson Disease | Movement Disorders | Neurodegenerative Diseases
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

Chronic Hepatic Impairment
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)

Movement Disorders | Antipsychotic Agents | Akathisia, Drug-Induced

3

Subscribe